AU2001250980A1 - Brca-1 regulators and methods of use - Google Patents

Brca-1 regulators and methods of use

Info

Publication number
AU2001250980A1
AU2001250980A1 AU2001250980A AU5098001A AU2001250980A1 AU 2001250980 A1 AU2001250980 A1 AU 2001250980A1 AU 2001250980 A AU2001250980 A AU 2001250980A AU 5098001 A AU5098001 A AU 5098001A AU 2001250980 A1 AU2001250980 A1 AU 2001250980A1
Authority
AU
Australia
Prior art keywords
brca
regulators
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250980A
Inventor
Jack Barber
Carmela Beger
Flossie Wong-Staal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusol Inc
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of AU2001250980A1 publication Critical patent/AU2001250980A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2001250980A 2000-03-23 2001-03-23 Brca-1 regulators and methods of use Abandoned AU2001250980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53605800A 2000-03-23 2000-03-23
US09/536,058 2000-03-23
PCT/US2001/009559 WO2001070982A2 (en) 2000-03-23 2001-03-23 Brca-1 regulators and methods of use

Publications (1)

Publication Number Publication Date
AU2001250980A1 true AU2001250980A1 (en) 2001-10-03

Family

ID=24136951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250980A Abandoned AU2001250980A1 (en) 2000-03-23 2001-03-23 Brca-1 regulators and methods of use

Country Status (5)

Country Link
EP (1) EP1268791A2 (en)
JP (1) JP2003527860A (en)
AU (1) AU2001250980A1 (en)
CA (1) CA2402834A1 (en)
WO (1) WO2001070982A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444257B (en) 1999-04-12 2001-07-01 Semiconductor Energy Lab Semiconductor device and method for fabricating the same
EP1280937A2 (en) * 2000-04-26 2003-02-05 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929668A1 (en) * 1996-09-04 1999-07-21 Onyx Pharmaceuticals, Inc. Modulators of brca1 activity
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
CA2335390A1 (en) * 1998-07-22 2000-02-03 Immusol Incorporated Substantially complete ribozyme libraries
WO2000056754A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 48 human secreted proteins
CA2395666A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Also Published As

Publication number Publication date
EP1268791A2 (en) 2003-01-02
WO2001070982A3 (en) 2002-08-22
WO2001070982A2 (en) 2001-09-27
JP2003527860A (en) 2003-09-24
CA2402834A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001285409A1 (en) Memory devices and methods for use therewith
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2001255199A1 (en) Ceramide derivatives and method of use
AU2002211717A1 (en) Stresscopins and their uses
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2002324895A1 (en) Cosmetic kit and method
AU2001273052A1 (en) Antifungal compounds and methods of use
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2001268236A1 (en) Use of aicar and related compounds
AU4432001A (en) Trityl-type compounds and their use
AU2001250980A1 (en) Brca-1 regulators and methods of use
AU2002256556A1 (en) Sea-trosy and related methods
AU2001296850A1 (en) Split-ubiquitin based reporter systems and methods of their use